Patients with myasthenia gravis (MG) largely expressed negative emotions around MG treatment and symptom burden in patient focus groups and on MG social media discussion boards.
The data come from a systematic review of over 90 studies between 1952 through 2022, which found that both prevalence and incidence rates have than doubled throughout the study period.
Researchers introduce a telemedicine system powered by artificial intelligence (AI) that automatically scores neuromuscular examinations, offering the potential to enhance patient monitoring, reduce variability in clinical trials, and improve access to care for neuromuscular disorders like myasthenia gravis.
This new study investigated the impact of COVID-19 on patients with myasthenia gravis, finding that although most patients did not experience severe COVID-19, a significant portion suffered postinfection exacerbations.
A new subgroup analysis of patients with muscle-specific tyrosine kinase (MuSK) autoantibody-positive (Ab+) myasthenia gravis (MG) shows rozanolixizumab (Rystiggo) contributes to meaningful symptom improvement.